Skip to main content
DeutschDE
European Commission logo print header

Hiv-1 reverse transcriptase inhibitor and its consequences for viral virulence

Ziel

VIRULENCE will provide a strategy against a major health threat: occurrence of resistance against therapeutic HIV/AIDS-measures. Reverse transcriptase inhibitors play an essential role HIV -treatment RT variants with reduced susceptibility to these inhibitors emerge even under potent combination therapies and may become less virulent. Thus, emergence of RTI resistance negatively affects the inhibitor efficacy but may also result in virus variants with reduced pathogenicity. VIRULENCE aims at elucidating clinical consequences of changes in viral fitness for optimal use of antiviral drugs. VIRULENCE is first to address this through development and validation of improved fitness assays and their application on existing well-defined longitudinal clinical cohorts. The mol. mechanisms for viral fitness and resistance will be elucidated and new compounds active against drug resistant HIV will be defined. This integrated approach will improve care of patients with limited therapeutic options.

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

CSC - Cost-sharing contracts

Koordinator

UNIVERSITY MEDICAL CENTRE UTRECHT
EU-Beitrag
Keine Daten
Adresse
Heidelberglaan 100
3584CX UTRECHT
Niederlande

Auf der Karte ansehen
Gesamtkosten
Keine Daten

Beteiligte (7)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 9 Dezember 2005

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/QLK2-CT-2002-01311/de

European Union, 2024